Cellect Biotechnology

Company Overview

Snapshot

Founded in June 2011 by Nuriel Chirich-Kasbian and Shai Yarkoni, Cellect Biotechnology operated with 11–50 employees. The company raised a total of $24.26M across 7 funding rounds. In November 2021, Cellect Biotechnology was acquired by Quoin Pharmaceuticals.

Business overview

Cellect Biotechnology develops solutions for immune system regeneration, leveraging a platform technology that identifies, selects, and utilizes stem cells based on their functional properties rather than appearance. The company's primary product, ApoGraft, is designed to improve bone marrow transplant outcomes by inducing apoptosis in mature cells while sparing stem cells. This differential sensitivity aims to enhance selectivity, specificity, and reduce toxicity, positioning Cellect Biotechnology's products as integral to bone marrow transplants and regenerative medicine. The company serves laboratories and healthcare providers within the Health Tech & Life Sciences sector, focusing on therapeutics, immunology, and cell therapy.

Strategic signal

In September 2021, Cellect Biotechnology announced the first U.S. patient transplantation using its ApoGraft bone marrow technology. This milestone signifies critical progress in the clinical validation and market expansion of its core therapeutic solution, demonstrating the company's advancement in bringing its regenerative medicine approach to a broader patient population and validating its technology for potential widespread adoption in bone marrow transplantation.

Company Intelligence Q&A

What was the most recent significant corporate event for Cellect Biotechnology?

In November 2021, Cellect Biotechnology was acquired by Quoin Pharmaceuticals, leading to its inactive status.

When did Cellect Biotechnology announce the first U.S. patient transplantation for ApoGraft?

In September 2021, Cellect Biotechnology announced the bone marrow transplantation of the first patient in the U.S. using its ApoGraft technology.

When did Cellect Biotechnology initiate its U.S. clinical trial for ApoGraft?

In October 2020, Cellect Biotechnology initiated a U.S. clinical trial for its ApoGraft product.

What was the outcome of the May 2020 public offering for Cellect Biotechnology?

In May 2020, Cellect Biotechnology announced the exercise of warrants, resulting in cash proceeds of approximately $1.5 million.

When did Cellect Biotechnology receive approval for its U.S. clinical trial?

In December 2019, Cellect Biotechnology received approval for its U.S. clinical trial.